In a filing, Apellis Pharmaceuticals Inc. revealed its Chief Development Officer Eisele Jeffrey unloaded Company’s shares for reported $0.11 million on Feb 23. In the deal valued at $68.76 per share,1,646 shares were sold. As a result of this transaction, Eisele Jeffrey now holds 53,883 shares worth roughly $ 3.51 million.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Then, Lewis Karen sold 1,104 shares, generating $75,911 in total proceeds. Upon selling the shares at $68.76, the Chief People Officer now owns 41,430 shares.
Before that, Machiels Alec sold 1,250 shares. Apellis Pharmaceuticals Inc. shares valued at $65,475 were divested by the Director at a price of $52.38 per share. As a result of the transaction, Machiels Alec now holds 267,641 shares, worth roughly $17.44 million.
Wells Fargo downgraded its Apellis Pharmaceuticals Inc. [APLS] rating to an Equal weight from a an Overweight in a research note published on Monday, January 03, 2023; the price target was decreased to $58 from $83. PT values the company’s stock at a premium of -12.34 to its Monday closing price. A number of analysts have revised their coverage, including Jefferies’s analysts, who decreased its forecast for the stock in early November from “a Buy” to “a Hold”. H.C. Wainwright began covering APLS with “Buy” recommendation on July 19, 2022.
Price Performance Review of APLS
On Monday, Apellis Pharmaceuticals Inc. [NASDAQ:APLS] saw its stock fall -2.29% to $65.16. On the same session, the stock had its day’s lowest price of $64.18, but rose to a high of $67.00. Over the last five days, the stock has gained 17.43%. Apellis Pharmaceuticals Inc. shares have risen nearly 26.01% since the year began. Nevertheless, the stocks have risen 50.38% over the past one year. While a 52-week high of $70.75 was reached on 02/23/23, a 52-week low of $33.32 was recorded on 01/05/23. SMA at 50 days reached $53.13, while 200 days put it at $53.29. A total of 2.3 million shares were traded, compared to the trading of 2.24 million shares in the previous session.
Levels Of Support And Resistance For APLS Stock
The 24-hour chart illustrates a support level at 63.89, which if violated will result in even more drops to 62.63. On the upside, there is a resistance level at 66.71. A further resistance level may holdings at 68.27. The Relative Strength Index (RSI) on the 14-day chart is 70.65, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 9.24, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 27.95%. Stochastics %K at 77.59% indicates the stock is a holding.
How much short interest is there in Apellis Pharmaceuticals Inc.?
A steep rise in short interest was recorded in Apellis Pharmaceuticals Inc. stocks on Jan 30, 2023, dropping by 60000.0 shares to a total of 9.11 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2022 was 9.17 million shares. There was a decline of -0.66%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 11.15% of the overall stock float, the days-to-cover ratio (short ratio) fell to 8.52.
Apellis Pharmaceuticals Inc. [APLS] – Who Are The Largest Shareholders?
In filings from Avoro Capital Advisor LLC, it is revealed that the company now owns 10,625,000 shares, or roughly 9.61% of the outstanding APLS shares. In other words, the investor’s shares have risen by 500,000 from its previous 13-F filing of 10125000.0. Additionally, The Vanguard Group, Inc. increased 2.00% of its stake after which the total value it holdings stand at $472,648,624, while Wellington Management Co. LLP reduced -12.05% of its stake to hold $461.79 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 457,425 shares of Apellis Pharmaceuticals Inc., while T. Rowe Price Investment Manageme bought 326,537 shares. At present, EcoR1 Capital, LLC is holding 5,183,431 shares valued at $273.32 million. Janus Henderson Investors US LLC owned 3,972,170 shares of the company at the time of its most recent 13F filing, worth $209.45 million.
According to FactSet, Apellis Pharmaceuticals Inc.’s share price will average $85.87 in the next year, based on opinions of analysts polled by the firm. This is up nearly 22.96 percent from its previous closing price of $66.69. Analysts expect Apellis Pharmaceuticals Inc. stock to reach the higher price of $139.00, while the lowest price estimate is $51.00. However, 16 analysts have rated APLS stock as an Overweight in their predictions for 2023.